Dr A Todrick (Department ofClinical Research, Crichton Royal Hospital, Dumfries) The papers presented support the inherent probability of correlation between plasma drug concentration and clinical effect. However, the binding of drugs by plasma proteins must be considered, since the effective concentration at the site of action depends on the level of free rather than total drug in the plasma. Drugs absorbed by plasma proteins are pharmacologically inactive, though in equilibrium with the active fraction. In practice, binding reduces the free concentration but also prolongs the action; it may either extend the time for which an adequate concentration acts or alternatively prevent one ever being attained. The degree of binding can range from almost zero to greater than 99-9 %, the phenothiazines and tranquillizers (75-95 % bound) occupying an intermediate position (Curry 1970 , Campbell & Todrick 1970 . Degree of binding is not the prime correlate of clinical effectiveness but modifies it. While the effective plasma concentrations of these psychotropic drugs are reduced to much the same degree, one should not ignore the possible variation with both drug and subject.
We sympathize with Dr Walter's difficulty in obtaining patients fitting his highly desirable clinical criteria, having ourselves met this problem in an acute form. The significant correlations obtained, despite small numbers, suggest that the underlying connexion must be close. On the basis of these and Dr Curry's observations, plasma concentration can now be accepted as superior to dose as a reflection of clinical effectiveness. It may be too early to demand plasma drug estimations routinely but research must undoubtedly continue.
In the relationship of plasma drug concentration to therapeutic action, the time factor has often appeared confusing. Dr Walter has observed a biphasic relationship between plasma concentration and duration of therapy; this may arise from induction of hydroxylating enzyme; if so, it should be absent in patients already on barbiturates. Like Dr Curry, I am puzzled by the delay in response to a stabilized chlorpromazine level. The theory that inactive precursors are converted to active metabolites is no longer favoured. We used to believe that much time was required to achieve a high brain level from a low free plasma concentration but the evidence is against it. It may be necessary to assume that the development of schizophrenia and depressive illness is only partially physiological or biochemical and that a second stage involves learning ofor conditioning forincorrect behaviour patterns. Pharmacological removal of the conditioning stimulus would leave the patient still incorrectly patterned, and unlearning would take time.
